RxDoctor Payments DataLook up a doctor →

Sanjay Kunapuli, MD

Interventional Cardiology · Houston, TXNPI 1457555021

Payments from drug & device makers

$266,642in general payments, 2019–2025

Across 789 payments — averaging $337.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$153K
  • Inari Medical, Inc.$45K
  • Esperion Therapeutics, Inc.$25K
  • Abbott$18K
  • Stryker$12K
  • Boston Scientific$3K
  • plus $11K from 48 others

What the payments were for

  • Consulting fees$25,2309%
  • Speaking & faculty fees$205,59577%
  • Travel & lodging$14,2825%
  • Food & beverage$21,3978%
  • Education$1280%
  • Entertainment$100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$266,642 in reported general payments places this provider in the 90th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$553,955
Medicare patients
1,282
Services billed
4,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban445$453,272
EliquisApixaban361$326,203
EntrestoSacubitril/Valsartan183$175,229
Repatha SureclickEvolocumab43$48,814
FarxigaDapagliflozin Propanediol39$36,713
BrilintaTicagrelor51$28,206
JardianceEmpagliflozin31$24,599
VascepaIcosapent Ethyl36$24,301
Metoprolol Succinate647$9,536
Ranolazine ErRanolazine99$8,634
Atorvastatin Calcium808$8,001
Rosuvastatin Calcium405$6,775
Ezetimibe186$5,147
Losartan Potassium533$4,754
Valsartan122$4,176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$153,301$453,272445 claims
PfizerEliquis$223$326,203361 claims
NovartisEntresto$862$175,229183 claims
AstraZenecaFarxiga, Brilinta$56$64,91990 claims
Boehringer IngelheimJardiance$137$24,59931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →